Indication

Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a specific, chronic, and progressive fibrosing interstitial lung disease of unknown etiology that is limited to the respiratory system. Read more about Idiopathic pulmonary fibrosis

135 drugs 94 manufacturers

Advertisement

Drugs that treat it

Common Idiopathic pulmonary fibrosis therapies.

Showing 118–126 of 135 drugs

PREDNISOLONE

GLUCOCORTICOSTEROIDS·TRICHINOSIS·+59
CHARTWELL GOVER

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Endo USA

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
ENOVACHEM MANUF

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
DR.REDDY'S LAB

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
APOTEX CORP

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
CIPLA USA, INC.

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
EDENBRIDGE/DEXC
Filter & compare in the drug finder →Opens the drug finder with Idiopathic pulmonary fibrosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis is a specific, chronic, and progressive fibrosing interstitial lung disease of unknown etiology that is limited to the respiratory system.

It primarily occurs in older adults, typically presenting in individuals over 50 to 60 years of age, and has a slight male predominance.

Pathophysiologically, repetitive micro-injury to the alveolar epithelium triggers aberrant wound healing, progressive fibroblast proliferation, and excessive extracellular matrix deposition, culminating in the destruction of normal lung architecture and a hallmark radiological or histopathological pattern of usual interstitial pneumonia.

Clinically, affected patients develop worsening exertional dyspnea, an intractable nonproductive cough, bibasilar inspiratory crackles, digital clubbing, and restrictive ventilatory impairment that often leads to respiratory failure.

Personalize your experience

Follow Idiopathic pulmonary fibrosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it